Dyslipidemia in Type 2 Diabetes

This study has been completed.

Sponsor:

Information provided by:

Merck

ClinicalTrials.gov Identifier:

NCT00547274

First received: October 19, 2007

Last updated: NA

Last verified: October 2007

History: No changes posted

Tracking Information

First Received Date ^ICMJE

October 19, 2007

Last Updated Date

October 19, 2007

Start Date ^ICMJE

May 2003

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Dyslipidemia in Type 2 Diabetes

Official Title ^ICMJE

Not Provided

Brief Summary

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 3

Study Design ^ICMJE

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Condition ^ICMJE

Diabetes Mellitus, Type II
Dyslipidemia

Intervention ^ICMJE

Drug: MK0767

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Not Provided

Completion Date

May 2004

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Men and non-pregnant females
Age greater than or equal to 21 years
Stop current diabetes therapy (if applicable)
Stop current statin therapy (if applicable)

Exclusion Criteria:

History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
Patients requiring treatment with corticosteroids for more than 14 consecutive days
Patients taking warfarin or warfarin-like anti-coagulants
Patients undergoing surgery within 30 days of Visit 1
Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
Patients with history of pancreatitis or uncontrolled high blood pressure

Gender

Both

Ages

21 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Not Provided

Administrative Information

NCT Number ^ICMJE

NCT00547274

Other Study ID Numbers ^ICMJE

2007_635

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Merck

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Study Director:

Medical Monitor

Merck

Information Provided By

Merck

Verification Date

October 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top